AR044335A1 - Derivados de (2-hidroxi-2-(4-hidroxi-3-hidroximetilfenil)-etilamino)-propilfenil como agonistas beta dos - Google Patents

Derivados de (2-hidroxi-2-(4-hidroxi-3-hidroximetilfenil)-etilamino)-propilfenil como agonistas beta dos

Info

Publication number
AR044335A1
AR044335A1 ARP040101650A ARP040101650A AR044335A1 AR 044335 A1 AR044335 A1 AR 044335A1 AR P040101650 A ARP040101650 A AR P040101650A AR P040101650 A ARP040101650 A AR P040101650A AR 044335 A1 AR044335 A1 AR 044335A1
Authority
AR
Argentina
Prior art keywords
hydroxi
group
derivatives
alkyl
formula
Prior art date
Application number
ARP040101650A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR044335A1 publication Critical patent/AR044335A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Se refiere a compuestos derivados de [2-hidroxi-2-(4-hidroxi-3-hidroximetilfenil)-etilamino]propifenil, y a procesos para la preparación de tales derivados, a intermedios usados en su preparación, a composiciones que los contienen y a los usos de tales derivados. Los compuestos de acuerdo con la presente son útiles en numerosas enfermedades, trastornos y afecciones, en particular enfermedades, trastornos y afecciones inflamatorias, alérgicas y respiratorias. Reivindicación 1: Un compuesto de fórmula (1), en la que el grupo (CH2)n-C(=O)Q1 está en la posición meta o para, n es 1 ó 2 y Q1 es un resto de grupo de fórmula (2), en donde al menos 2 de R1 a R4 son iguales a H, y un grupo *-N(R8)-Q2-A, en el que Q2 es un enlace sencillo o un alquileno C1-4, R8 es H o alquilo C1-4, p es 1 ó 2 y A es piridilo o un grupo de fórmula (3), en la que al menos 2 de R1 a R5 son iguales a H, en la que R1, R2, R3, R4 y R5 son iguales o diferentes y se seleccionan entre H, alquilo C1-4, OR6, SR6, halo, CF3, OCF3, COOR6, SO2NR6R7, CONR6R7, NR6R7, NHCOR6, donde R6 y R7 son iguales o diferentes y se seleccionan entre H o alquilo C1-4 y el * representa el punto de unión al grupo carbonilo, o si es apropiado, sus sales y/o isómeros, tautómeros, solvatos o variaciones isotópicas farmacéuticamente aceptable del mismo.
ARP040101650A 2003-05-15 2004-05-14 Derivados de (2-hidroxi-2-(4-hidroxi-3-hidroximetilfenil)-etilamino)-propilfenil como agonistas beta dos AR044335A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03010944A EP1477167A1 (en) 2003-05-15 2003-05-15 [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
GBGB0329874.2A GB0329874D0 (en) 2003-05-15 2003-12-23 Compounds useful for the treatment of diseases

Publications (1)

Publication Number Publication Date
AR044335A1 true AR044335A1 (es) 2005-09-07

Family

ID=33454327

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101650A AR044335A1 (es) 2003-05-15 2004-05-14 Derivados de (2-hidroxi-2-(4-hidroxi-3-hidroximetilfenil)-etilamino)-propilfenil como agonistas beta dos

Country Status (29)

Country Link
EP (2) EP1477167A1 (es)
JP (1) JP3966897B2 (es)
KR (1) KR100749990B1 (es)
CN (1) CN1791407A (es)
AP (1) AP2005003443A0 (es)
AR (1) AR044335A1 (es)
AT (1) ATE413879T1 (es)
AU (1) AU2004237952A1 (es)
BR (1) BRPI0410391A (es)
CA (1) CA2525006A1 (es)
CL (1) CL2004000963A1 (es)
CO (1) CO5700776A2 (es)
DE (1) DE602004017710D1 (es)
DK (1) DK1624868T3 (es)
EA (1) EA200501615A1 (es)
EC (1) ECSP056164A (es)
ES (1) ES2314395T3 (es)
GB (1) GB0329874D0 (es)
IS (1) IS8080A (es)
MA (1) MA27840A1 (es)
MX (1) MXPA05012329A (es)
NL (1) NL1026203C2 (es)
NO (1) NO20055854L (es)
OA (1) OA13165A (es)
PA (1) PA8603001A1 (es)
PE (1) PE20060095A1 (es)
TW (1) TW200505865A (es)
UY (1) UY28317A1 (es)
WO (1) WO2004100950A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548235A (en) * 2004-01-22 2010-05-28 Pfizer Sulfonamide derivatives as beta2 agonists for the treatment of diseases
UA84048C2 (ru) 2004-01-22 2008-09-10 Пфайзер Инк. Производные сульфонамида для лечения заболеваний, способ их получения (варианты), фармацевтическая композиция на их основе
BRPI0508927A (pt) * 2004-03-17 2007-08-14 Pfizer compostos úteis para o tratamento de doenças
WO2005092860A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
WO2005092887A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2618089A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR20090075714A (ko) 2006-10-30 2009-07-08 노파르티스 아게 소염제로서의 헤테로시클릭 화합물
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
NZ594157A (en) 2008-12-30 2013-07-26 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US5629200A (en) * 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
EP0824519A1 (en) * 1995-05-10 1998-02-25 Pfizer Inc. Beta-adrenergic agonists
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist

Also Published As

Publication number Publication date
DE602004017710D1 (de) 2008-12-24
KR100749990B1 (ko) 2007-08-16
OA13165A (en) 2006-12-13
IS8080A (is) 2005-10-20
GB0329874D0 (en) 2004-01-28
WO2004100950A1 (en) 2004-11-25
PE20060095A1 (es) 2006-02-18
ES2314395T3 (es) 2009-03-16
MXPA05012329A (es) 2006-01-30
EP1624868A1 (en) 2006-02-15
ATE413879T1 (de) 2008-11-15
NO20055854L (no) 2006-02-10
JP2007503458A (ja) 2007-02-22
TW200505865A (en) 2005-02-16
PA8603001A1 (es) 2004-12-16
CA2525006A1 (en) 2004-11-25
DK1624868T3 (da) 2009-02-23
AU2004237952A1 (en) 2004-11-25
CO5700776A2 (es) 2006-11-30
AP2005003443A0 (en) 2005-12-31
NL1026203A1 (nl) 2004-11-16
MA27840A1 (fr) 2006-04-03
BRPI0410391A (pt) 2006-07-18
KR20060017607A (ko) 2006-02-24
EA200501615A1 (ru) 2006-06-30
JP3966897B2 (ja) 2007-08-29
ECSP056164A (es) 2006-04-19
NL1026203C2 (nl) 2005-07-26
EP1624868B1 (en) 2008-11-12
EP1624868B9 (en) 2009-08-12
UY28317A1 (es) 2004-12-31
EP1477167A1 (en) 2004-11-17
CN1791407A (zh) 2006-06-21
CL2004000963A1 (es) 2005-03-18

Similar Documents

Publication Publication Date Title
AR044335A1 (es) Derivados de (2-hidroxi-2-(4-hidroxi-3-hidroximetilfenil)-etilamino)-propilfenil como agonistas beta dos
AR038834A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco
UY28339A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
EA200400616A1 (ru) ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β
AR032361A1 (es) Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
ES505960A0 (es) Un procedimiento para la obtencion de un derivado acilico sustituido del compuesto acido 1,2,3,4-tetrahidro-3-isoqui- nolein-carboxilico
AR044476A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
AR003453A1 (es) Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores
YU75590A (sh) 3-supstituisani-2-oksindol derivati i postupak za njihovo dobijanje
AR067060A1 (es) Derivados de guanina policiclicos y sus metodos de uso
AR048939A1 (es) Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios.
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR055041A1 (es) Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
EA200000188A1 (ru) Производные 2,3-диарил-пиразоло[1,5-b]-пиридазинов, их получение и их применение в качестве ингибиторов циклооксигеназы-2 (цог-2)
IL103301A (en) Pyrimidine nucleoside derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
SE9203825L (sv) Dubbelt verkande inhibitorer foer no-syntas och cyklooxygenas, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
AR038404A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye
UY30617A1 (es) Derivados sustituidos del carbamato de 1-(9-{[(2r)-2-{4-hidroxi-3-[(metilsulfonil)amino]fenil}etil]amino}nonil)piperidin-4-ilo, sus sales y solvatos farmacéuticamente aceptables y aplicaciones
AR038835A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para tratar enfermedades, el compuesto activo, una composicion farmaceutica que incluye la combinacion y uso de esta para la fabricacion de un farmaco
AR065464A1 (es) Derivados de nicotinamida. composiciones farmaceuticas
ES8607256A1 (es) Un procedimiento para la preparacion de fenotiazonas halogenadas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure